Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Swallow, D L
Right arrow Articles by Kampfner, G L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swallow, D L
Right arrow Articles by Kampfner, G L
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 41:322-332 (1985)
© 1985 The British Council


research-article

THE LABORATORY SELECTION OF ANTIVIRAL AGENTS

D L Swallow and G L Kampfner

ICI Pharmaceuticals Division Macclesfield Cheshire

Abstract

The major disease targets for antiviral chemotherapy are influenza, rhinovirus colds and herpetic infections Some success has been achieved against influenza with 1-amino adamantane (amantadine), and several new alicyclic amines are at the development stage. There are many organic compounds, covering a wide range of chemical types, which will inhibit very effectively most or all strains of rhinovirus in vitro, but all have failed to inhibit significantly disease development in infected human volunteers. Most success has been achieved with anti-herpetic drugs, and a variety of nucleoside analogues ar now available for clinical use. Primary testing methods for potential antiviral agents rely on high-through-put methods for detecting inhibition of virus replication in cell cultures. Secondary screening of active compounds is often done in organ culture e.g. tracheal tissue explants. In-vivo evaluation is done in animal models of the human disease, where available. Prolonged safety testing is required before human trials can be started.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.